Otezla(apremilast)
Apremilast, Otezla (apremilast) is a small molecule pharmaceutical. Apremilast was first approved as Otezla on 2014-03-21. It is used to treat psoriatic arthritis in the USA. It has been approved in Europe to treat psoriasis and psoriatic arthritis. The pharmaceutical is active against 3',5'-cyclic-AMP phosphodiesterase 4B, 3',5'-cyclic-AMP phosphodiesterase 4D, 3',5'-cyclic-AMP phosphodiesterase 4C, and 3',5'-cyclic-AMP phosphodiesterase 4A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Apremilast, Otezla (discontinued: Apremilast)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| apremilast | ANDA | 2021-07-01 |
| otezla | New Drug Application | 2024-05-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriatic arthritis | EFO_0003778 | D015535 | L40.5 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
APREMILAST, OTEZLA, AMGEN INC | |||
| 2026-07-20 | M-299 | ||
| 2026-07-19 | ODE-248 | ||
| 2024-12-20 | I-884 | ||
HCPCS
No data
Clinical
Clinical Trials
157 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 7 | 13 | 3 | 11 | 35 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 3 | 8 | 2 | 8 | 21 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 2 | 8 | 2 | 8 | 20 |
| Parapsoriasis | D010267 | — | L41 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Behcet syndrome | D001528 | EFO_0003780 | M35.2 | — | 1 | 3 | — | 1 | 5 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | — | 2 | — | — | 2 |
| Oral ulcer | D019226 | HP_0000155 | — | — | — | 2 | — | — | 2 |
| Covid-19 | D000086382 | — | — | — | — | 1 | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | 1 | — | — | 1 |
| Spondylarthritis | D025241 | — | — | — | — | 1 | — | — | 1 |
| Spondylitis | D013166 | — | M46.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 2 | — | — | — | 2 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 2 | — | — | — | 2 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | 1 | — | — | — | 1 |
| Lichen planus | D008010 | — | L43 | — | 1 | — | — | — | 1 |
| Genital diseases | D000091662 | — | — | — | 1 | — | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | — | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Apremilast |
| INN | apremilast |
| Description | Apremilast is a member of the class of isoindoles that is isoindole-1,3-dione substituted at position 4 by an acetamido group and at position 1 by a 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl group. Used for treatment of psoriatic arthritis. It has a role as a phosphodiesterase IV inhibitor and a non-steroidal anti-inflammatory drug. It is an aromatic ether, a N-acetylarylamine, a sulfone and a member of phthalimides. |
| Classification | Small molecule |
| Drug class | antiasthmatics/antiallergics (not acting primarily as antihistamines): type IV phosphodiesterase |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC |
Identifiers
| PDB | — |
| CAS-ID | 608141-41-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL514800 |
| ChEBI ID | 78540 |
| PubChem CID | 11561674 |
| DrugBank | DB05676 |
| UNII ID | UP7QBP99PN (ChemIDplus, GSRS) |
Target
Agency Approved
PDE4B
PDE4B
PDE4D
PDE4D
PDE4A
PDE4A
Organism
Homo sapiens
Gene name
PDE4B
Gene synonyms
DPDE4
NCBI Gene ID
Protein name
3',5'-cyclic-AMP phosphodiesterase 4B; cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Protein synonyms
cAMP-specific phosphodiesterase 4B, DPDE4, dunce-like phosphodiesterase E4, PDE32, phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)
Uniprot ID
Mouse ortholog
Pde4b (18578)
3',5'-cyclic-AMP phosphodiesterase 4B (Q9QXI7)
Alternate
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,518 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
132,838 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use